首页   按字顺浏览 期刊浏览 卷期浏览 Management of Immune-Mediated Uveitis
Management of Immune-Mediated Uveitis

 

作者: Justine R. Smith,   James T. Rosenbaum,  

 

期刊: BioDrugs  (ADIS Available online 2000)
卷期: Volume 13, issue 1  

页码: 9-20

 

ISSN:1173-8804

 

年代: 2000

 

出版商: ADIS

 

关键词: Azathioprine, therapeutic use;Corticosteroids, therapeutic use;Cyclophosphamide, therapeutic use;Cyclosporin, therapeutic use;Methotrexate, therapeutic use;Nonsteroidal antiinflammatories, therapeutic use;Reviews on treatment;Uveitis, treatment

 

数据来源: ADIS

 

摘要:

Immune-mediated uveitis is a collective term referring to a group of potentially blinding intraocular inflammations which may coexist with systemic inflammatory diseases. T lymphocytes appear to play an important pathogenic role in uveitis, and these cells are therefore the logical target of drug therapy. Corticosteroids act nonspecifically, but are highly effective in controlling the inflammation rapidly. They are administered locally when disease is confined to the anterior portion of the eye. However, posterior eye involvement often requires systemic corticosteroid therapy, carrying a high risk of serious adverse effects when used for extended periods. In this situation, steroid-sparing agents are used.Few relevant randomised, controlled clinical trials have been performed, and the choice of systemic immunosuppressive regimen is usually guided by individual patient characteristics, cost, drug availability and physician preference. Patients should actively participate in therapeutic decision-making.Our first choice for steroid-sparing medication is often methotrexate, an antimetabolite which carries a low risk of adverse reactions when appropriately prescribed and monitored, is relatively inexpensive, and has once-weekly ease of use. For more severe uveitis, we may combine the immunomodulating agent cyclosporin with methotrexate and a corticosteroid. Azathioprine and cyclophosphamide are other treatment options. Steroid-sparing drugs also have significant potential for causing adverse effects, albeit less frequently than corticosteroids. Future therapies aim to reduce this problem by increasing the specificity of the therapeutic action.

 

点击下载:  PDF (113KB)



返 回